KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Long-Term Investments (2016 - 2025)

Astrana Health's Long-Term Investments history spans 9 years, with the latest figure at $38.5 million for Q2 2025.

  • For Q2 2025, Long-Term Investments rose 15.56% year-over-year to $38.5 million; the TTM value through Jun 2025 reached $38.5 million, up 15.56%, while the annual FY2024 figure was $39.3 million, 52.55% up from the prior year.
  • Long-Term Investments for Q2 2025 was $38.5 million at Astrana Health, down from $39.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $45.8 million in Q2 2023 and bottomed at $9.9 million in Q1 2024.
  • The 5-year median for Long-Term Investments is $40.3 million (2022), against an average of $38.2 million.
  • The largest annual shift saw Long-Term Investments skyrocketed 65.49% in 2021 before it crashed 77.03% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $41.7 million in 2021, then fell by 3.39% to $40.3 million in 2022, then crashed by 36.04% to $25.8 million in 2023, then skyrocketed by 52.55% to $39.3 million in 2024, then dropped by 2.2% to $38.5 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's Long-Term Investments are $38.5 million (Q2 2025), $39.3 million (Q4 2024), and $34.6 million (Q3 2024).